Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling
Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling
复制标题
DOI：
10.1002/nbm.1762
复制
发表时间：
2012-02-01
影响因子：
2.9
通讯作者：
Gribbestad, Ingrid S.
中科院分区：
文献类型：
--
作者：
Cao, Maria D.;Sitter, Beathe;Gribbestad, Ingrid S.
目的：本研究旨在评估MR代谢图谱是否可用于预测局部晚期乳腺癌患者在新辅助化疗(NAC)期间的长期生存和监测治疗反应。方法：采集33例患者治疗前后的高分辨魔角旋转(HR-MAS)磁共振波谱。组织中胆碱代谢物(TCHO)、甘氨酸和牛磺酸的浓度用电子参照物访问信号的体内浓度(ERETIC)进行评估，并用受试者工作特性(ROC)曲线来确定它们预测患者生存和治疗反应的潜力。通过遗传算法偏最小二乘判别分析(GA-PLS-DA)，HR-MAS光谱分析得到的代谢产物谱与长期生存和治疗反应相关。结果：长期生存患者(生存5年)与死于癌症复发的患者治疗前的MR代谢特征不同，表现为Tcho水平升高，乳酸水平降低(P<0.05)。
Purpose - This study aimed to evaluate whether MR metabolic profiling can be used for prediction of long-term survival and monitoring of treatment response in locally advanced breast cancer patients during neoadjuvant chemotherapy (NAC). Methods: High resolution magic angle spinning (HR MAS) MR spectra of pre- and post-treatment biopsies from 33 patients were acquired. Tissue concentrations of choline-containing metabolites (tCho), glycine and taurine were assessed using electronic reference to access in vivo concentration (ERETIC) of the signal and receiver operating characteristic (ROC) curves was used to define their potential to predict patient survival and treatment response. The metabolite profiles obtained by HR MAS spectroscopy were related to long-term survival and treatment response by genetic algorithm partial least squares discriminant analysis (GA PLS-DA).Results - Different pre-treatment MR metabolic profiles characterized by higher levels of tCho and lower levels of lactate were observed in patients with long-term survival (>= 5years, survivors) compared to patients who died of cancer recurrence (